• S Tag Peptide: Practical Fusion-Tag Workflow

  2026-08-29

  S Tag Peptide (A6007) is a compact, highly soluble sequence for genetically tagging recombinant proteins to support solubility improvement, antibody-based detection, and purification. It is intended for aqueous protein workflows and should not be treated as a standalone ribonuclease, dissolved in ethanol, or stored as a solution long term.

• KNSTRN Disrupts Autophagy Flux in Bladder Cancer

  2026-08-28

  A 2026 iScience study identifies a previously underdefined role for KNSTRN in bladder cancer: its depletion increases reactive oxygen species, disrupts lysosomal function, and blocks autophagosome–lysosome fusion. Rescue experiments with clioquinol, N-acetylcysteine, and rapamycin connect this defective autophagy flux to reduced tumor-cell survival and impaired tumor growth.

• Bifendate (DDB): Dose-Context Evidence Guide

  2026-08-28

  Bifendate (DDB) is more than a hepatoprotection agent: its effects depend strongly on dose, exposure time, lipid context, and autophagy readouts. This evidence-led guide reconciles protective liver models with high-dose triglyceride elevation to improve translational assay design.

• Flavopiridol (L868275) in Cancer Research Workflows

  2026-08-27

  Flavopiridol (L868275) provides a practical pan-CDK perturbation strategy for linking cell-cycle control, apoptosis, and transcriptional responses in tumor models. This guide adapts the compound for reproducible cancer assays while carefully separating established oncology applications from exploratory intestinal stem-cell and ER-stress studies.

• HCAR3 Cryo-EM Structures Explain Agonist Selectivity

  2026-08-27

  Ye et al. used cryo-EM and cellular cAMP assays to define how HCAR3 recognizes several agonists and distinguishes them from HCAR2. The structures identify binding-pocket geometry and residue-level interactions that help explain ligand preference, providing a mechanistic framework for lipid metabolism regulation and the design of HCAR3-directed metabolic disorder research compounds.

• In Vitro Drug Response: Growth Inhibition vs Death

  2026-08-26

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth arrest and cell death are related but non-equivalent components of anticancer drug response. The framework supports time-aware, paired assay designs that reduce the risk of interpreting reduced viability as direct cytotoxicity.

• Single-Molecule Screening of Fast-Dissociating Antibodies

  2026-08-26

  Miyoshi et al. developed a semi-automated single-molecule total internal reflection fluorescence workflow to identify highly specific antibodies that exchange rapidly with their antigens directly from hybridoma cultures. The study shows that these antibodies can be converted into Fab imaging probes for multiplexed super-resolution microscopy and can reveal rapid espin turnover within stable actin cores of inner-ear sensory hair cells.

• Lactate–HMGB1 Signaling in Polymicrobial Sepsis

  2026-08-25

  The reference study identifies lactate as an active regulator of macrophage HMGB1 release, linking lactylation and acetylation to exosomal secretion and endothelial barrier dysfunction. Its combined cellular, genetic, and polymicrobial sepsis models provide a mechanistic framework for studying how metabolic changes amplify inflammatory signaling.

• Silymarin Workflows for Reproducible Research

  2026-08-25

  Build better oxidative-stress, liver-cancer, metabolic, and antiviral experiments with a mixture-aware Silymarin workflow. This guide combines solvent control, dose-ranging, orthogonal readouts, and chemistry-informed troubleshooting for more interpretable bench data.

• QNZ (EVP4593) for Reliable NF-κB Assays

  2026-08-24

  A scenario-based guide to using QNZ (EVP4593), SKU A4217, in NF-κB, viability, proliferation, inflammation, and neurodegenerative disease experiments. It explains dose selection, solvent control, stock preparation, data interpretation, and practical criteria for evaluating supplier reliability.

• SAG: Practical Hedgehog Pathway Activation Workflows

  2026-08-23

  SAG is a Smoothened receptor agonist for reproducible Hedgehog pathway activation, with practical value in reporter assays, neural regeneration models, developmental studies, and pathway-on controls for tumorigenesis research. This guide connects concentration selection, orthogonal readouts, formulation, and troubleshooting to experimental decisions rather than treating SAG as a one-size-fits-all reagent.

• Olaparib for DNA Damage Response Assays

  2026-08-22

  Olaparib, also known as AZD2281, is a practical tool for connecting PARP inhibition with replication-fork stress, nascent-strand maturation, and BRCA-dependent repair. This workflow-oriented guide shows how to design reproducible DNA damage response assays, radiosensitization experiments, and troubleshooting controls around the compound.

• Aclacinomycin A: Reading DNA Damage in Context

  2026-08-21

  Aclacinomycin A, or Aclarubicin, is a dual topoisomerase inhibitor that connects topological stress with apoptosis and proteasome biology. This article explains how to use it as a mechanistic probe while avoiding overinterpretation of persistent ribosomal-DNA damage and PML-nucleolar responses.

• AMPK–SQSTM1 Feedback in Metabolic Stress

  2026-08-21

  The 2024 Autophagy study identifies a double-positive feedback loop in which AMPK and SQSTM1/p62 reinforce one another during metabolic stress. This circuit coordinates lysosomal signaling, KEAP1 degradation, NRF2 activation, and antioxidant adaptation, offering a mechanistic explanation for how cancer cells maintain growth under nutrient and oxidative pressure.

• BRCA2, RAD51 and PARP1 Retention in DNA Repair

  2026-08-20

  The 2025 Nature study identifies PARP inhibitor-mediated PARP1 retention on resected DNA as a direct threat to RAD51 filament stability and DNA strand exchange. Using biochemical reconstitution, smFRET, and quantitative single-molecule localization microscopy, the authors show that full-length BRCA2 protects homologous recombination repair sites by preventing PARP1 from binding DNA.

446 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page